10-Q: Natural Alternatives International Reports Q3 2024 Results with Revenue Decline and Net Loss

Natural Alternatives International reported a decrease in net sales and a net loss for the third quarter of fiscal year 2024, primarily due to reduced orders in their private-label contract manufacturing segment.

Summary

• Natural Alternatives International (NAII) experienced a 23% decrease in net sales for the three months ended March 31, 2024, totaling $25.1 million, compared to $32.7 million in the same period last year.
• The company reported a net loss of $1.6 million for the quarter, or $0.27 per share, compared to a net loss of $2.4 million, or $0.41 per share, in the prior year.
• For the nine months ended March 31, 2024, net sales decreased by 29% to $84.3 million, compared to $118.1 million in the same period last year.
• The net loss for the nine-month period was $5.3 million, or $0.91 per share, compared to a net income of $0.5 million, or $0.08 per share, in the prior year.
• Private-label contract manufacturing sales decreased by 26% in the quarter and 31% over the nine-month period, primarily due to reduced orders from major customers.
• Patent and trademark licensing revenue increased by 13% in the quarter and 28% over the nine-month period, driven by increased royalty income and sales.
• The company's gross profit margin decreased to 7.6% for the quarter and 6.5% for the nine-month period, compared to 4.2% and 11.0% respectively in the prior year.
• NAII temporarily closed its Carlsbad, California powder processing facility in October 2023 due to excess customer inventory, but plans to reopen it in May 2024.
• The company's credit facility was amended in February 2024, reducing borrowing capacity to $12.5 million and increasing the interest rate.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to significant revenue decline, net losses, and reduced gross profit margins. While there are some positive aspects like increased licensing revenue and the reopening of the Carlsbad facility, the overall financial performance is concerning.

Positives

• Patent and trademark licensing revenue increased by 13% in the quarter and 28% over the nine-month period.
• The company plans to reopen its Carlsbad, California powder processing facility in May 2024.
• NAII had $12.4 million in cash and cash equivalents as of March 31, 2024.
• The company is focusing on diversifying its sales base and expanding its beta-alanine business.

Negatives

• Net sales decreased by 23% in the third quarter of fiscal 2024 and 29% over the nine-month period.
• The company experienced a net loss of $1.6 million in the third quarter and $5.3 million over the nine-month period.
• Private-label contract manufacturing sales declined significantly due to reduced customer orders.
• Gross profit margin decreased to 7.6% for the quarter and 6.5% for the nine-month period.
• The company's credit facility was amended, reducing borrowing capacity and increasing interest rates.

Risks

• The company's revenue is highly dependent on a few large private-label contract manufacturing customers.
• The loss of key raw material suppliers could negatively impact the business.
• The company is subject to fluctuations in foreign currency exchange rates.
• Geopolitical instability and conflicts could disrupt supply chains and impact operations.
• The company's ability to maintain or increase beta-alanine royalty and licensing revenue depends on market development and patent protection.
• The company is subject to various legal proceedings that could result in significant financial and managerial resources.

Future Outlook

The company anticipates a net loss in the fourth quarter of fiscal 2024 and an overall net loss for fiscal 2024. They plan to continue focusing on leveraging their facilities, expanding their beta-alanine business, and improving operational efficiencies.

Management Comments

• Management is monitoring the conflict in Israel and Gaza and any broader economic effects from the crisis.
• Management believes their recent efforts to refine formulations and product offerings will be positively received and result in significant opportunity for increased SR CarnoSyn sales.
• Management expects the annualized fiscal 2024 revenue concentration for their largest customer to be flat to slightly higher as compared to fiscal 2023.

Industry Context

The nutritional supplement industry is competitive and subject to fluctuations in consumer demand and supply chain disruptions. NAII's results reflect challenges in the private-label contract manufacturing segment, which is sensitive to customer inventory levels and market conditions. The company's focus on expanding its beta-alanine business aligns with the growing wellness and healthy aging markets.

Comparison to Industry Standards

• The decrease in revenue and gross profit margin is worse than some of the larger players in the contract manufacturing space such as Catalent and Lonza, who have reported more stable results.
• The increase in patent and trademark licensing revenue is a positive sign, but the overall financial performance is below industry benchmarks for profitability.
• The company's reliance on a few large customers is a risk, which is not uncommon in the contract manufacturing industry, but the level of concentration is higher than some of its peers.
• The temporary closure of the Carlsbad facility and the subsequent reopening is a significant event that is not typical for companies in this sector, indicating operational challenges.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and decreased revenue.
• Employees may be affected by the temporary closure of the Carlsbad facility and potential restructuring.
• Customers may experience supply chain disruptions due to the temporary closure of the Carlsbad facility.
• Suppliers may be impacted by changes in order volumes and potential shifts in sourcing.

Next Steps

• The company plans to reopen its Carlsbad, California powder processing facility in May 2024.
• NAII will continue sales and marketing activities to promote CarnoSyn and SR CarnoSyn beta-alanine.
• The company will focus on diversifying its sales base and expanding its beta-alanine business.
• NAII will continue to monitor the impact of geopolitical conflicts on its business.

Key Dates

Keywords

contract manufacturing, beta-alanine, CarnoSyn, SR CarnoSyn, patent licensing, nutritional supplements, financial results, revenue, net loss, gross profit, credit facility